Oncology
MET inhibitor for metastatic NSCLC with MET exon 14 skipping mutations
Capmatinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping. It is the first MET inhibitor specifically approved for this molecular subtype of lung cancer.
Capmatinib is a highly selective, potent MET kinase inhibitor. It works by blocking the MET signaling pathway, which is abnormally activated in tumors with MET exon 14 skipping mutations. By inhibiting MET, capmatinib prevents downstream signaling cascades that promote tumor cell survival, proliferation, and migration.
The recommended dosage is 400 mg taken orally twice daily, with or without food. Treatment should continue until disease progression or unacceptable toxicity occurs.